DEFLAGYN® Vaginal Gel and Spontaneous Remission and Regression of Unclear Cervical Smears and HPV High-risk Infections

NAActive, not recruitingINTERVENTIONAL
Enrollment

168

Participants

Timeline

Start Date

November 8, 2022

Primary Completion Date

May 31, 2025

Study Completion Date

July 31, 2025

Conditions
Cervix DysplasiaHPV Infection
Interventions
DEVICE

DEFLAGYN vaginal gel

DEFLAGYN is a vaginal gel, classified as a medical device, containing silica and citric acid, which binds pathogens, inhibits their spread and exerts an antioxidant effect. It is applied intravaginally (through an applicator) and used for 3 months.

Trial Locations (1)

44625

Marien Hospital Herne, Herne

All Listed Sponsors
lead

Ruhr University of Bochum

OTHER